Chemistry:Neluxicapone

From HandWiki

Neluxicapone (INN) is a catechol O-methyltransferase (COMT) inhibitor which has not been marketed as of 2024.[1][2][3] The drug is a nitrocatechol and is structurally related to other catechol COMT inhibitors like entacapone, tolcapone, and nebicapone.[4][3] COMT inhibitors are used in conjunction with levodopa in the treatment of Parkinson's disease.[4] Neluxicapone was first described in the literature by 2018.[3][1] Its INN was designated by the World Health Organization (WHO) in 2019.[2]

References

  1. ↑ 1.0 1.1 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2018 (StemBook2018). World Health Organization. 2018. No. WHO/EMP/RHT/TSN/2018.1. https://iris.who.int/bitstream/handle/10665/275695/WHO-EMP-RHT-TSN-2018.1-eng.pdf#page=81. "-capone catechol-O-methyltransferase (COMT) inhibitors. entacapone (65), nebicapone (96), neluxicapone (119), nitecapone (62), opicapone (103), tolcapone (66)" 
  2. ↑ 2.0 2.1 "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 81". WHO Drug Information 33 (1): 43–133. 2019. https://iris.who.int/bitstream/handle/10665/330896/DI331-43-133-eng.pdf#page=46. 
  3. ↑ 3.0 3.1 3.2 "Neluxicapone". PubChem. U.S. National Library of Medicine. https://pubchem.ncbi.nlm.nih.gov/compound/90015465. 
  4. ↑ 4.0 4.1 "Toxicology and safety of COMT inhibitors". Basic Aspects of Catechol-O-Methyltransferase and the Clinical Applications of its Inhibitors. International Review of Neurobiology. 95. 2010. pp. 163–189. doi:10.1016/B978-0-12-381326-8.00007-7. ISBN 978-0-12-381326-8. 




Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Neluxicapone&oldid=4243563"